Home
|
Contact
|
Pharmacovigilance
|
Medical Information
|
ITA
ENG
Welcome to
Chiesi group
Enter at least 3 characters
About us
History
Mission and Values
Governance
Benefit Corporation and B Corp
Annual and Sustainability Report
Chiesi in the world
Main areas
Research and Development
Clinical Trial Transparency and Data Sharing
Chiesi Clinical Studies
Manufacturing plants
Partnering
Why Chiesi as a partner
Therapeutic Focus
Who we are
Where we are
Events
Open Innovation - The Impulse
Digital Health
Working at Chiesi
Sustainability
Our approach
Ethics and Transparency
Patients at the Center
Environment
Global Value Chain
Chiesi people
Communities
Media area
News
Press Release
Contact
Home
>
Press release
Elgan Pharma and Chiesi Group Announce First Participating Infants Dosed in...
Nazareth, Israel and Parma, Italy, June 05, 2025 – Elgan Pharma Ltd. and Chiesi Farmaceutici S.p.A today announced the dosing of the first...
Purpose First: Chiesi Publishes 2024 Sustainability Report
Chiesi Group delivers on transformational strategy with FY2024 double-digit...
ARCHIVE PRESS RELEASE
Maria Paola Chiesi received by the President of the Italian Republic for the 2020 Bellisario Award ceremony
15 Ottobre 2020
We ACT Day 2020: the third edition of Chiesi’s event for a sustainable future
24 Settembre 2020
Chiesi Farmaceutici President appointed Knight of the Légion d’Honneur
18 Settembre 2020
Moderna and Chiesi Group Establish Collaboration to Discover and Develop mRNA Therapeutics for Pulmonary Arterial Hypertension (PAH).
17 Settembre 2020
Chiesi publishes its annual report: Group generates almost €2 billion and obtains B Corp certification in 2019
16 Luglio 2020
Bioasis and Chiesi Group to Host Webcast on July 16, 2020
10 Luglio 2020
Thomas Eichholtz appointed new Head of Global Research and Development at the Chiesi Group
02 Luglio 2020
Bioasis and Chiesi Group Announce Rare Diseases Strategic Alliance
29 Giugno 2020
Chiesi Group increases support measures and announces new funds for employees, patients and healthcare providers in response to COVID-19 pandemic
27 Marzo 2020
Chiesi Group Announces Establishment of New Global Rare Diseases Division
06 Febbraio 2020
<<
1
2
3
4
5
6
7
8
9
CHIESI ON THE WEB
Australia
Chiesi Australia
Austria
Chiesi Pharmaceuticals GmbH
Belgium
Chiesi SA/NV
Brazil
Chiesi Farmacêutica Ltda
Bulgaria
Chiesi Bulgaria EOOD
Canada
Chiesi Canada Corp
China
Chiesi Pharmaceutical (Shanghai) Co., Ltd
Czech Republic
Chiesi CZ s.r.o.
Denmark
Chiesi Pharma AB
Finland
Chiesi Pharma AB
France
Chiesi SAS
Germany
Chiesi GmbH
Greece
Chiesi Hellas Α.Ε.Β.Ε.
Hungary
Chiesi Hungary Kft.
Italy
CHIESI Italia S.p.A.
Japan
Chiesi Pharma Japan K.K.
Mexico
CHIESI MÉXICO
Norway
Chiesi Pharma AB
Pakistan
CHIESI PAKISTAN
Poland
Chiesi Poland
Romania
Chiesi România S.r.l.
Russian Federetion
Chiesi Pharmaceuticals LLC
Slovak Republic
Chiesi Slovakia s.r.o
Slovenia
Chiesi Slovenija, d.o.o
Spain
CHIESI ESPAÑA S.A.U
Sweden
Chiesi Pharma AB
The Netherlands
Chiesi Pharmaceuticals B.V.
Turkey
Chiesi İlaç Ticaret A.Ş
United Kingdom
Chiesi Limited
United States
Chiesi Usa, Inc.